Convalescent plasma in Covid-19: Possible mechanisms of action.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible of the coronavirus disease 2019 (COVID-19) pandemic. Therapeutic options including antimalarials, antivirals, and vaccines are under study. Meanwhile the current pandemic has called attention over old therapeutic tools to tr...

Full description

Autores:
Tipo de recurso:
Fecha de publicación:
2020
Institución:
Universidad del Rosario
Repositorio:
Repositorio EdocUR - U. Rosario
Idioma:
eng
OAI Identifier:
oai:repository.urosario.edu.co:10336/24587
Acceso en línea:
https://doi.org/10.1016/j.autrev.2020.102554
https://repository.urosario.edu.co/handle/10336/24587
Palabra clave:
ACE-2 receptor
COVID-19
Convalescent plasma
Coronavirus
Cytokines
Intravenous immunoglobulins
Neutralizing antibodies
SARS-Cov-2
Rights
License
Abierto (Texto Completo)
id EDOCUR2_b480dbe01d2eb67b8456ac685a2133b1
oai_identifier_str oai:repository.urosario.edu.co:10336/24587
network_acronym_str EDOCUR2
network_name_str Repositorio EdocUR - U. Rosario
repository_id_str
spelling 11105414856001022961735600383619336003143448f-dab7-4338-8665-9d38661461758d2fbe92-da8c-46a5-ab8d-8b5ea2cd1d5f5224970152483526600d3968e45-396a-404d-94c5-bfb4bbcb454215d20733-4d96-4082-b857-2d58264922aecb44c18d-c693-4ba5-ba89-8993a5634ee0ef6fa7cf-59f5-4c86-bc53-d389160d7ddf19474778600531672886002020-06-11T13:20:49Z2020-06-11T13:20:49Z2020Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible of the coronavirus disease 2019 (COVID-19) pandemic. Therapeutic options including antimalarials, antivirals, and vaccines are under study. Meanwhile the current pandemic has called attention over old therapeutic tools to treat infectious diseases. Convalescent plasma (CP) constitutes the first option in the current situation, since it has been successfully used in other coronaviruses outbreaks. Herein, we discuss the possible mechanisms of action of CP and their repercussion in COVID-19 pathogenesis, including direct neutralization of the virus, control of an overactive immune system (i.e., cytokine storm, Th1/Th17 ratio, complement activation) and immunomodulation of a hypercoagulable state. All these benefits of CP are expected to be better achieved if used in non-critically hospitalized patients, in the hope of reducing morbidity and mortality.application/pdfhttps://doi.org/10.1016/j.autrev.2020.1025541873-0183https://repository.urosario.edu.co/handle/10336/24587engElsevier BV102554102554Autoimmunity reviewsAutoimmunity reviews, ISSN:1873-0183 (2020); pp. 102554-102554Abierto (Texto Completo)http://purl.org/coar/access_right/c_abf2instname:Universidad del Rosarioreponame:Repositorio Institucional EdocURACE-2 receptorCOVID-19Convalescent plasmaCoronavirusCytokinesIntravenous immunoglobulinsNeutralizing antibodiesSARS-Cov-2Convalescent plasma in Covid-19: Possible mechanisms of action.articleArtículohttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_6501Rojas Quintana, Manuel EduardoRodríguez Velandia, Yhojan AlexisAcosta Ampudia, Yeny YasbleidyCamacho, BernardoGallo, Juan EstebanRojas-Villarraga, AdrianaRamírez Santana, Heily CarolinaDiaz-Coronado, Juan CManrique, RubenMantilla, Ruben DShoenfeld, YehudaAnaya, Juan-ManuelMonsalve Carmona, Diana Marcela10336/24587oai:repository.urosario.edu.co:10336/245872021-10-06 16:52:40.122https://repository.urosario.edu.coRepositorio institucional EdocURedocur@urosario.edu.co
dc.title.spa.fl_str_mv Convalescent plasma in Covid-19: Possible mechanisms of action.
title Convalescent plasma in Covid-19: Possible mechanisms of action.
spellingShingle Convalescent plasma in Covid-19: Possible mechanisms of action.
ACE-2 receptor
COVID-19
Convalescent plasma
Coronavirus
Cytokines
Intravenous immunoglobulins
Neutralizing antibodies
SARS-Cov-2
title_short Convalescent plasma in Covid-19: Possible mechanisms of action.
title_full Convalescent plasma in Covid-19: Possible mechanisms of action.
title_fullStr Convalescent plasma in Covid-19: Possible mechanisms of action.
title_full_unstemmed Convalescent plasma in Covid-19: Possible mechanisms of action.
title_sort Convalescent plasma in Covid-19: Possible mechanisms of action.
dc.subject.keyword.spa.fl_str_mv ACE-2 receptor
COVID-19
Convalescent plasma
Coronavirus
Cytokines
Intravenous immunoglobulins
Neutralizing antibodies
SARS-Cov-2
topic ACE-2 receptor
COVID-19
Convalescent plasma
Coronavirus
Cytokines
Intravenous immunoglobulins
Neutralizing antibodies
SARS-Cov-2
description Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible of the coronavirus disease 2019 (COVID-19) pandemic. Therapeutic options including antimalarials, antivirals, and vaccines are under study. Meanwhile the current pandemic has called attention over old therapeutic tools to treat infectious diseases. Convalescent plasma (CP) constitutes the first option in the current situation, since it has been successfully used in other coronaviruses outbreaks. Herein, we discuss the possible mechanisms of action of CP and their repercussion in COVID-19 pathogenesis, including direct neutralization of the virus, control of an overactive immune system (i.e., cytokine storm, Th1/Th17 ratio, complement activation) and immunomodulation of a hypercoagulable state. All these benefits of CP are expected to be better achieved if used in non-critically hospitalized patients, in the hope of reducing morbidity and mortality.
publishDate 2020
dc.date.accessioned.none.fl_str_mv 2020-06-11T13:20:49Z
dc.date.available.none.fl_str_mv 2020-06-11T13:20:49Z
dc.date.created.spa.fl_str_mv 2020
dc.type.eng.fl_str_mv article
dc.type.coarversion.fl_str_mv http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_6501
dc.type.spa.spa.fl_str_mv Artículo
dc.identifier.doi.none.fl_str_mv https://doi.org/10.1016/j.autrev.2020.102554
dc.identifier.issn.none.fl_str_mv 1873-0183
dc.identifier.uri.none.fl_str_mv https://repository.urosario.edu.co/handle/10336/24587
url https://doi.org/10.1016/j.autrev.2020.102554
https://repository.urosario.edu.co/handle/10336/24587
identifier_str_mv 1873-0183
dc.language.iso.none.fl_str_mv eng
language eng
dc.relation.citationEndPage.none.fl_str_mv 102554
dc.relation.citationStartPage.none.fl_str_mv 102554
dc.relation.citationTitle.none.fl_str_mv Autoimmunity reviews
dc.relation.ispartof.spa.fl_str_mv Autoimmunity reviews, ISSN:1873-0183 (2020); pp. 102554-102554
dc.rights.coar.fl_str_mv http://purl.org/coar/access_right/c_abf2
dc.rights.acceso.spa.fl_str_mv Abierto (Texto Completo)
rights_invalid_str_mv Abierto (Texto Completo)
http://purl.org/coar/access_right/c_abf2
dc.format.mimetype.none.fl_str_mv application/pdf
dc.publisher.spa.fl_str_mv Elsevier BV
institution Universidad del Rosario
dc.source.instname.spa.fl_str_mv instname:Universidad del Rosario
dc.source.reponame.spa.fl_str_mv reponame:Repositorio Institucional EdocUR
repository.name.fl_str_mv Repositorio institucional EdocUR
repository.mail.fl_str_mv edocur@urosario.edu.co
_version_ 1814167742393090048